JP2020514324A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514324A5 JP2020514324A5 JP2019542200A JP2019542200A JP2020514324A5 JP 2020514324 A5 JP2020514324 A5 JP 2020514324A5 JP 2019542200 A JP2019542200 A JP 2019542200A JP 2019542200 A JP2019542200 A JP 2019542200A JP 2020514324 A5 JP2020514324 A5 JP 2020514324A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- cells
- oncolytic virus
- infiltrating
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025037414A JP2025106256A (ja) | 2017-02-03 | 2025-03-10 | 腫瘍溶解性ウイルス療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762454526P | 2017-02-03 | 2017-02-03 | |
| US62/454,526 | 2017-02-03 | ||
| PCT/US2018/016912 WO2018145033A1 (en) | 2017-02-03 | 2018-02-05 | Oncolytic virus therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025037414A Division JP2025106256A (ja) | 2017-02-03 | 2025-03-10 | 腫瘍溶解性ウイルス療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020514324A JP2020514324A (ja) | 2020-05-21 |
| JP2020514324A5 true JP2020514324A5 (https=) | 2021-03-18 |
| JP7724601B2 JP7724601B2 (ja) | 2025-08-18 |
Family
ID=63041101
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542200A Active JP7724601B2 (ja) | 2017-02-03 | 2018-02-05 | 腫瘍溶解性ウイルス療法 |
| JP2025037414A Pending JP2025106256A (ja) | 2017-02-03 | 2025-03-10 | 腫瘍溶解性ウイルス療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025037414A Pending JP2025106256A (ja) | 2017-02-03 | 2025-03-10 | 腫瘍溶解性ウイルス療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12350303B2 (https=) |
| EP (1) | EP3577132B1 (https=) |
| JP (2) | JP7724601B2 (https=) |
| KR (2) | KR102932184B1 (https=) |
| CN (2) | CN118662538A (https=) |
| AU (3) | AU2018215558B2 (https=) |
| CA (1) | CA3052463A1 (https=) |
| WO (1) | WO2018145033A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7724601B2 (ja) | 2017-02-03 | 2025-08-18 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 腫瘍溶解性ウイルス療法 |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| EP4054612A4 (en) * | 2019-11-07 | 2023-08-02 | Baylor College of Medicine | ONCOLYTIC VIROTHERAPY AND IMMUNOTHERAPY |
| EP4061417A4 (en) * | 2019-11-20 | 2023-10-11 | University of Pittsburgh - of the Commonwealth System of Higher Education | VACCINIA VIRUSES AND METHOD FOR USING VACCINIA VIRUSES |
| EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
| CA3158133A1 (en) * | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
| CN117957323A (zh) * | 2021-08-13 | 2024-04-30 | 深圳市华药康明生物药业有限责任公司 | 经修饰的痘苗病毒及其应用 |
| CN113846068A (zh) * | 2021-08-25 | 2021-12-28 | 居颂光 | 融合基因ril-7重组牛痘病毒及其在制备抗肿瘤药物中的应用 |
| CN113832115A (zh) * | 2021-08-25 | 2021-12-24 | 居颂光 | 融合基因ril-7联合ccl19重组溶瘤牛痘病毒及其在制备抗肿瘤药物中的应用 |
| CN114058597A (zh) * | 2021-10-28 | 2022-02-18 | 钟莉娉 | 生物制导溶瘤病毒制剂及应用 |
| CN115948411A (zh) * | 2022-11-23 | 2023-04-11 | 郑州大学 | 竞争性表达的il-12和il-23及其基因、重组载体和在制备治疗肿瘤药物中的应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US6277368B1 (en) | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
| US5891432A (en) | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
| WO2000073479A1 (en) | 1999-05-28 | 2000-12-07 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| WO2003017944A2 (en) | 2001-08-27 | 2003-03-06 | Greenville Hospital System | Gpi-anchored cytokines |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US9045727B2 (en) | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
| KR20120002613A (ko) | 2002-08-12 | 2012-01-06 | 제네렉스, 인코포레이티드 | 폭스바이러스 및 암과 관련된 방법 및 조성물 |
| KR101772375B1 (ko) | 2005-09-07 | 2017-08-29 | 신라젠(주) | Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법 |
| KR20080084528A (ko) | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| DE102008023820A1 (de) * | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| ES2733211T3 (es) | 2011-04-15 | 2019-11-28 | Genelux Corp | Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas |
| US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| WO2014138314A1 (en) * | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Oncolytic virus |
| RS65104B1 (sr) | 2013-08-22 | 2024-02-29 | Univ Pittsburgh Commonwealth Sys Higher Education | Onkolitičke imunoterapije |
| BR112016009465A8 (pt) | 2013-10-28 | 2018-01-30 | Univ Pittsburgh Commonwealth Sys Higher Education | vetor de hsv oncolítico. |
| EP3197911A4 (en) | 2014-09-22 | 2018-06-20 | Intrexon Corporation | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
| KR20170074235A (ko) | 2014-10-31 | 2017-06-29 | 메사추세츠 인스티튜트 오브 테크놀로지 | 면역 세포로의 생체분자의 전달 |
| AU2016232009B2 (en) * | 2015-03-17 | 2021-07-15 | Tilt Biotherapeutics Oy | Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto |
| HRP20200439T1 (hr) * | 2015-04-30 | 2020-06-12 | Psioxus Therapeutics Limited | Onkolitički adenovirus koji kodira protein b7 |
| EP3347473A4 (en) * | 2015-09-09 | 2019-04-10 | Tvax Biomedical I, LLC | METHOD FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ATTACHMENT THERAPY |
| WO2017165464A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| SI3458083T1 (sl) | 2016-05-18 | 2023-03-31 | Modernatx, Inc. | Polinukleotidi, ki kodirajo interlevkin-12 (IL12) in njihova uporaba |
| WO2017209053A1 (ja) | 2016-05-30 | 2017-12-07 | アステラス製薬株式会社 | 新規な遺伝子組換えワクシニアウイルス |
| EP3523323A4 (en) | 2016-10-07 | 2020-06-17 | Board of Regents, The University of Texas System | T-CELLS WITH EXPRESSION OF MEMBRANE-ANCHORED IL-12 FOR THE TREATMENT OF CANCER |
| JP7724601B2 (ja) | 2017-02-03 | 2025-08-18 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 腫瘍溶解性ウイルス療法 |
| JP7285220B2 (ja) | 2017-05-18 | 2023-06-01 | モデルナティエックス インコーポレイテッド | 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子 |
| EP3898997A4 (en) | 2018-12-21 | 2022-11-16 | Ottawa Hospital Research Institute | MODIFIED ORTHOPOXVIRUS VECTORS |
| EP4061417A4 (en) * | 2019-11-20 | 2023-10-11 | University of Pittsburgh - of the Commonwealth System of Higher Education | VACCINIA VIRUSES AND METHOD FOR USING VACCINIA VIRUSES |
-
2018
- 2018-02-05 JP JP2019542200A patent/JP7724601B2/ja active Active
- 2018-02-05 CN CN202410646571.6A patent/CN118662538A/zh active Pending
- 2018-02-05 WO PCT/US2018/016912 patent/WO2018145033A1/en not_active Ceased
- 2018-02-05 CA CA3052463A patent/CA3052463A1/en active Pending
- 2018-02-05 US US16/482,623 patent/US12350303B2/en active Active
- 2018-02-05 KR KR1020197025815A patent/KR102932184B1/ko active Active
- 2018-02-05 EP EP18747947.2A patent/EP3577132B1/en active Active
- 2018-02-05 AU AU2018215558A patent/AU2018215558B2/en active Active
- 2018-02-05 KR KR1020267005584A patent/KR20260042553A/ko active Pending
- 2018-02-05 CN CN201880020756.9A patent/CN110520438A/zh active Pending
-
2023
- 2023-05-15 AU AU2023203000A patent/AU2023203000B2/en active Active
-
2025
- 2025-03-10 JP JP2025037414A patent/JP2025106256A/ja active Pending
- 2025-06-11 US US19/235,000 patent/US20250332208A1/en active Pending
-
2026
- 2026-03-09 AU AU2026201764A patent/AU2026201764A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514324A5 (https=) | ||
| US20230399615A1 (en) | Icos critically regulates the expansion and function of inflammatory human th17 cells | |
| AU2018244221B2 (en) | ANK and IL-12 compositions and methods | |
| ES2535835T3 (es) | Composiciones para la preparación de células dendríticas maduras | |
| JP2020514324A (ja) | 腫瘍溶解性ウイルス療法 | |
| JP6615148B2 (ja) | 免疫療法を用いたｉｌ−１２の誘導 | |
| JP2011036251A (ja) | ウイルスベクターおよびその遺伝子治療のための使用 | |
| CN110075275B (zh) | IL-36β的应用 | |
| CN101580817A (zh) | 含有细胞因子诱导杀伤细胞的细胞群的制造方法 | |
| AU2006288348A1 (en) | Method for activation treatment of antigen-presenting cell | |
| CN103110939A (zh) | 诱导肿瘤特异性免疫的疫苗及其应用 | |
| US20250163376A1 (en) | Method for inducing and amplifying stem memory t cell in vitro | |
| ES2660577T3 (es) | Células que expresan características y propiedades citolíticas de Th1 | |
| JP2003506095A5 (https=) | ||
| ES2445184T3 (es) | Procedimiento de proliferación de células LAK | |
| CN119909172B (zh) | 过表达slc29a1用于增强t细胞内外活性的应用 | |
| CN115845061A (zh) | Parkin抑制剂在增强免疫细胞抗肿瘤效应中的用途 | |
| JP5966129B2 (ja) | 免疫賦活剤 | |
| KR20250097905A (ko) | Mait 세포 활성화 조성물 및 방법 | |
| HK1256146A1 (zh) | 溶瘤病毒作为用於治疗肿瘤和/或癌症的免疫刺激剂的应用 | |
| Gonzalez-Carmona et al. | [29] VACCINATION WITH DENDRITIC CELLS TRANSDUCED WITH A CD40L-EXPRESSING ADENOVIRUS AND AN AFP-ENCODING ADENOVIRUS INDUCES INHIBITION OF SUBCUTANEOUS HEPATOCELLULAR TUMOR GROWTH IN MICE |